FTT Research, page-85

As mentioned in my previous FTT research post.

'On 31 December 2019 the Company entered into an agreement with JEM Pharmaceuticals Pty Ltd, which is a consulting company of Non-Executive Director, Mr John Michailidis. The consulting agreement is for services associated with the scientific and commercial diligence review processes for asset/s under consideration by the Company for potential acquisition or licence.'

Below is the screenshot of page 11 of the Annual Report released on 19 February 2020.

Not sure if anyone researched John Michailidis's background but this man has more than just an impressive Resume.

A nice summary of the John's profile was covered by small caps: https://*********.com.au/impression-healthcare-recruits-big-pharma-executive-cannabinoid-drug-discovery/

As stated from the above link, John started off his career at Roche and he was a former president and CEO at Roche Korea, responsible for launching new treatments in the foreign market and tripling sales, as well as his role with Teva as managing director of the ANZ division. These are big roles that add to his extensive 30 years in the industry no doubt, but to me it's the smaller roles he had which weren't mentioned in the above link that impress me the most.
https://www.linkedin.com/in/john-michailidis-maicd-harvard-business-school-3650955/?originalSubdomain=au

You can see from his linkedin profile, he has an MBA from Harvard, in between his positions at Roche and Teva, he was also CEO for a number of companies:

CEO at Orphan Pharmaceuticals (2005 - 2009)

- Melbourne based private specialist pharmaceutical company

- Double digit revenue growth every year during John's tenure as CEO

- Sales revenue $40 million, EBITDA $13 million for FY18

- Eventually bought out by Sigma (ASX: SIG) for $130 million

Sigma buy out Orphan for $130 million in 2009

CEO at Avipep Pharmaceuticals (2009 - 2012)

- Successfully initiated and completed the company's first in men phase I trial, assisted by UK investment under Strategic Translation Award, first company in Australia to do so

- Raised over $10 million in funding for company's cancer treatment clinical trials, including a $2 million Victorian Science Agency grant

- https://neoskosmos.com/en/2422/avipeo-clinical-trials/

- Clinical trial details here https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ID=362774

Founder of JEM Pharmaceuticals (2012 - present)

- Private company founded by John in 2012, focused on novel specialized product treating serious diseases and conditions

- Has 14 employees and sales revenue of $3 million

- https://www.zoominfo.com/c/jem-pharmaceuticals-pty-ltd/358832174

- One of their products on market: https://www.veilcream.com.au/

From a simple google search, several articles can be found covering John's profile.

So as you can see, every leadership role that John has taken in the past, from Roche, to Orphan, then Avipep, lastly JEM and Teva, he was able to make a significant positive impact for the company. Overlooking clinical trials, bringing new products to market as well as growing sales are all John's specialty and has been proven with his 30 years experience in the pharmaceutical and healthcare industry. Also last year John was appointed as IHL Executive position for a short period.

In my opinion John is the perfect select to find and perform due diligence review process of a potential new asset/ assets. As investors, we always look for management teams with a successful and proven track record.

Good luck to all. Please don't forget these are my opinion only and do your own research.